Elevated Homocysteine (Hyperhomocysteinemia)

Elevated Homocysteine (Hyperhomocysteinemia)

Homocysteine is a sulfur-containing amino acid produced during the conversion of methionine, and it is not consumed in food. It sits at a metabolic junction: it can be remethylated back to methionine, a reaction requiring folate and vitamin B12, or committed to the transsulfuration pathway, which requires vitamin B6. When any of the three vitamins runs short, or when the enzymes handling them work slowly, the amino acid accumulates in plasma. Elevated concentrations occur in 5 to 10 percent of the general population and in as many as 30 to 40 percent of older adults.

The condition is otherwise silent. It produces no symptoms of its own and is identified on a blood panel, usually ordered because of premature atherosclerosis or an unexplained thromboembolic event, both of which are associated with sustained elevation.

Folate is the single ingredient graded against this endpoint here, at Grade B on 30 studies and 30,000 participants. The size of that participant total relative to the number of studies reflects the field's history: folate was tested in large randomised cardiovascular trials rather than in many small biochemical ones. Those trials established a reliable finding and a disappointing one at the same time. Supplementation lowers circulating homocysteine dependably, but the reviews of randomised homocysteine-lowering vitamin trials did not find the corresponding reduction in cardiovascular events that the epidemiology had implied ^[1]. The biomarker moves; the outcome has been harder to move with it.

Genetics explains part of the variation between individuals. The C677T polymorphism in the methylenetetrahydrofolate reductase gene yields an enzyme with reduced thermostability, and homozygous carriers show higher homocysteine and lower folate status than non-carriers on identical intakes ^[2]. Response to supplementation therefore varies by genotype in a way that population averages conceal.

The other established drivers are acquired rather than inherited. Chronic kidney disease impairs clearance. Hypothyroidism slows the relevant metabolic steps. Methotrexate and phenytoin interfere with folate metabolism directly. Advancing age contributes through declining B12 absorption, since atrophic gastritis and reduced intrinsic factor are common after the seventh decade, and low B-vitamin status in ageing populations has been described as a public health problem in its own right ^[3].

Most of the research attention on elevated homocysteine has migrated from vascular endpoints to cognitive ones. Reviews of homocysteine, B vitamins and cognitive impairment have examined whether the association observed in cohort studies survives randomisation, and the answer has depended heavily on the baseline vitamin status of the population studied and on the cognitive endpoint chosen ^[4]. Trials in populations already replete with folate have less room to demonstrate anything, a limitation that applies equally to the cardiovascular literature.

For anyone monitoring this marker, the practical points are that the measurement is affected by fasting state and sample handling, that B12 deficiency should be identified before folate is supplemented alone, and that a normalised laboratory value is evidence of a corrected pathway rather than of a corrected risk.